HIV 1 News and Research

RSS

Time to increase efforts against HIV/AIDS, TB

In a Huffington Post opinion piece, Kolleen Bouchane, director of ACTION, asks whether President Barack Obama will "heed Archbishop [Desmond] Tutu's call to action" in a recent Washington Post opinion piece "and do his part to end AIDS."

1 Oct 2011

Express Scripts launches suite of services through HealthBridge Pharma & Biotech

Express Scripts has launched a suite of services for pharmaceutical and biotech companies through HealthBridge Pharma & Biotech, providing a single-solution approach to patient care.

1 Oct 2011

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

Vertex Pharmaceuticals Incorporated today announced that abstracts from its hepatitis C program, including two late-breaking posters from studies of INCIVEK (telaprevir) tablets and VX-222, were accepted for presentation at The Liver Meeting, the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

1 Oct 2011

UCSF protein researcher wins NIH's Early Independence Award

James Fraser, PhD, a protein researcher who studies structural biology at the California Institute for Quantitative Biosciences (QB3) at the University of California, San Francisco (UCSF), is one of 10 recipients of a prestigious award for young scientists given for the first time by the National Institutes of Health.

1 Oct 2011

USAID interviews Kenyan government staff regarding Cabinet memorandum outlining HIV program fundraising options

USAID's "IMPACTblog" interviews Regina Ombam, head of strategy for the Kenya National AIDS Control Council (NACC), and Irene Mukui, the antiretroviral therapy (ART) program manager for Kenya's National AIDS and STI Control Program, regarding a Cabinet memorandum prepared by the NACC in March that outlines ways to raise funds for HIV programming.

1 Oct 2011

Members of MAPRx coalition urge supercommittee to protect Part D program

Writing on behalf of millions of Medicare beneficiaries with chronic health conditions who rely on Part D for their essential medications, 26 members of the Medicare Access for Patients Rx (MAPRx) coalition sent a joint letter urging members of the joint deficit panel ("supercommittee") to reject proposals to increase Medicare beneficiary cost-sharing, raise coinsurance, and freeze income thresholds as they seek ways to reduce federal spending.

30 Sep 2011

Two UTA scientists win 2011 PECASE award for innovative research

Two scientists from The University of Texas at Austin are among the 2011 recipients of Presidential Early Career Awards for Scientists and Engineers (PECASE), the highest honor bestowed by the United States government on science and engineering professionals in the early stages of their independent research careers.

30 Sep 2011

Small Phase I trial shows HIV vaccine candidate is most powerful to date

Researchers at the Spanish Superior Scientific Research Council (CSIC) have successfully completed a small Phase I human clinical trial of an HIV vaccine candidate that granted 90 percent of 30 study participants an immunological response against the virus, Gizmag reports.

30 Sep 2011

Adult male circumcision not a cost effective anti-HIV tactic, panel of economists says

A panel of economists commissioned by the Copenhagen Consensus Centre who "conducted a first-ever cost-benefit analysis of the top AIDS-fighting approaches by comparing the costs of prevention and treatment options per lives saved ... said Wednesday that adult male circumcision, a global priority for preventing HIV infection, is not nearly as cost-effective as other methods of prevention," USA Today reports.

30 Sep 2011

Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated

"The Microbicide Trials Network (MTN), which is funded by the U.S. National Institutes of Health, on Wednesday announced that it decided to stop one arm of a study involving more than 5,000 women in South Africa, Zimbabwe, and Uganda" after "an interim review of the ongoing trial by an independent monitoring board found that the drug tenofovir when used as pre-exposure prophylaxis (PrEP) had less effect in protecting women than anticipated," Science Magazine's "Science Insider" blog reports.

30 Sep 2011

Global Fund board supports recommendations of Independent Review Panel, will implement 'wide-reaching reforms'

"The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria approved an action plan Monday in response to recommendations made recently by the High-Level Independent Review Panel on Fiduciary Controls and Oversight Mechanism (HLP)," the Center for Global Health Policy's "Science Speaks" blog reports, adding, "The board stated that it accepts the underlying analysis made by the panel and that it 'presents a compelling case for a rapid and urgent transformation of the Global Fund.'"

30 Sep 2011

Sexually transmitted infection epidemic worries health experts

Researchers at the University of New South Wales (NSW) revealed that new cases of gonorrhea and Chlamydia are on the rise in Australia, particularly among young members of indigenous communities.

29 Sep 2011

Poor hospital supplies could spell danger for vulnerable patients

It was found that most hospitals operate with less than a month's supply of many essential medicines, leaving patients vulnerable if local distributors are unable to import them through fragile international supply chains.

29 Sep 2011

Powerful HIV vaccine being tested on humans

Spanish researchers have developed a prototype of a vaccine against the AIDS-causing HIV virus that is “much more powerful” than those made to date.

29 Sep 2011

Oral tenofovir discontinued in HIV clinical trial

A large-scale clinical trial evaluating whether daily use of an oral tablet or vaginal gel containing antiretroviral drugs can prevent HIV infection in women is being modified because an interim review found that the study cannot show that one of the study products, oral tenofovir, marketed under the trade name Viread, is effective.

29 Sep 2011

Low-tech, inexpensive interventions for bedsores could benefit long-term care residents

Researchers at the University of Toronto have found that low-tech, inexpensive interventions for bedsores could improve health for long-term care residents and reduce health-care costs for the facilities that house them.

29 Sep 2011

AASLD publishes updated practice guidelines on hepatitis C

On Monday, September 26, 2011, the American Association for the Study of Liver Diseases published online at its journal Hepatology's website an update to its practice guidelines for hepatitis C – "An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases."

29 Sep 2011

VOICE HIV prevention trial to discontinue use of tenofovir tablets

VOICE, an HIV prevention trial evaluating two antiretroviral (ARV)-based approaches for preventing the sexual transmission of HIV in women - daily use of one of two different ARV tablets or of a vaginal gel - will be dropping one of the oral tablets from the study.

29 Sep 2011

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

Phase I clinical trials developed by Spanish Superior Scientific Research Council (CSIC) together with Gregorio Mara--n Hospital in Madrid and Cl-nic Hospital in Barcelona, reveals MVA-B preventive vaccine's immune efficiency against Human's immunodeficiency virus (HIV).

28 Sep 2011

'Urgent action' needed to prevent resistance to antiretroviral therapy

"The clear pattern of increasing antiretroviral resistance in lower-income settings must be considered in the context of the worldwide HIV-control agenda," especially because "the increasing rates of antiretroviral resistance in low-income settings represent a potential threat to the emerging treatment-as-prevention strategy," Evan Wood and Julio Montaner of the BC Centre for Excellence in HIV/AIDS write in a Lancet Infectious Diseases opinion piece.

28 Sep 2011

HIV 1 News and Research

Time to increase efforts against HIV/AIDS, TB

Express Scripts launches suite of services through HealthBridge Pharma & Biotech

Vertex announces abstracts from hepatitis C program to be presented at The Liver Meeting

UCSF protein researcher wins NIH's Early Independence Award

USAID interviews Kenyan government staff regarding Cabinet memorandum outlining HIV program fundraising options

Members of MAPRx coalition urge supercommittee to protect Part D program

Two UTA scientists win 2011 PECASE award for innovative research

Small Phase I trial shows HIV vaccine candidate is most powerful to date

Adult male circumcision not a cost effective anti-HIV tactic, panel of economists says

Microbicide Trials Network stops tenofovir arm of study after findings show drug less effective than anticipated

Global Fund board supports recommendations of Independent Review Panel, will implement 'wide-reaching reforms'

Sexually transmitted infection epidemic worries health experts

Poor hospital supplies could spell danger for vulnerable patients

Powerful HIV vaccine being tested on humans

Oral tenofovir discontinued in HIV clinical trial

Low-tech, inexpensive interventions for bedsores could benefit long-term care residents

AASLD publishes updated practice guidelines on hepatitis C

VOICE HIV prevention trial to discontinue use of tenofovir tablets

Phase I clinical trials reveal MVA-B preventive vaccine's immune efficiency against HIV

'Urgent action' needed to prevent resistance to antiretroviral therapy

Decoding Cannabis: Differentiating Hemp and Marijuana

Deciphering the Microbiome with The Microsetta Initiative

Leveraging the power of automation to boost research

Latest News